連續生物製程市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、製程、應用、最終用戶、地區及競爭格局分類），2021-2031年

全球連續生物加工市場預計將從 2025 年的 2.6487 億美元成長到 2031 年的 4.6439 億美元，複合年成長率為 9.81%。

該領域的核心在於生物材料在加工單元中連續流動，同時添加培養基並收穫最終產品。這種方法的主要驅動力在於，需要在提高高混合生產效率和柔軟性的同時，最大限度地減少資本支出和設施面積。合約研發生產機構 (CDMO) 的強勁成長進一步推動了這一領域的擴張，這些機構擴大採用這些多功能系統來處理各種不同的產品線。正如 2024 年 CPHI 年度報告指出，49% 的受訪製藥企業高管對合約服務的未來成長持「非常樂觀」的態度，這凸顯了該行業對外部合作夥伴在推動高效工作流程方面的高度依賴。

儘管連續生物程序具有諸多優勢，但其廣泛應用仍面臨諸多挑戰，主要與製程控制的複雜性和法規遵循有關。即時監測關鍵品質屬性所需的高階流程分析技術（PAT）構成了一項重要的技術門檻。此外，對連續自動化檢驗的需求，以及熟練掌握此類動態系統管理技能的人員短缺，都可能阻礙連續生物程序的推廣應用，尤其是在那些習慣於傳統間歇式工藝的現有工廠中。

市場促進因素

製程分析技術 (PAT) 和自動化技術的進步是全球連續生物製程市場的關鍵驅動力，它們能夠實現即時品管並最大限度地減少人為錯誤。整合這些自動化系統使製造商能夠持續監控關鍵程式參數，並在不停止生產的情況下即時修正偏差。雖然這種轉型在技術上具有挑戰性，但對於維持生物製藥的嚴格監管標準至關重要，這促使製造商升級舊有系統。根據 CRB 於 2024 年 10 月發布的《展望：生命科學報告》，約 31% 的受訪產業專業人士將數位化和自動化轉型計劃視為其下一個主要資本投資，這凸顯了該產業對技術升級的重視。

向模組化和靈活化生產設施的轉型將進一步推動市場成長，使企業能夠快速回應不斷變化的生產需求和多元化的產品平臺。與傳統的固定式不銹鋼設施相比，模組化單元可快速重新配置以適應不同的生產配置，從而顯著降低多產品生產的進入門檻並減少設施佔地面積。大型製藥企業為提升生產敏捷性而進行的投資正是這一趨勢的例證。根據《貝克爾醫院評論》2024年11月一篇關於賽諾菲新工廠的報導，該公司正在新加坡建造一座價值6億美元的工廠，旨在同時生產多達四種生物製劑。這項措施與整個產業的趨勢相符：2024年CRB數據顯示，四分之三的受訪者目前已安裝連續生產技術或計畫在未來五年內安裝。

市場挑戰

連續生物製程的廣泛應用主要受到嚴格的製程管制要求和相關監管不確定性的限制。與傳統的間歇式製程不同，連續式工作流程需要即時監控和自動化回饋迴路來維持產品質量，這就需要先進的製程分析技術（PAT）。這種技術複雜性導致了陡峭的操作學習曲線，因為製造商必須確保動態控制系統持續穩定運作並檢驗。因此，許多公司對從成熟的間歇式製程轉型持謹慎態度，擔心無法向監管機構證明其控制的穩定性，可能導致違規和生產延誤。

近期行業數據也印證了這種合規性方面的擔憂：根據國際製藥工程協會 (ISPE) 2024 年的一項調查，近 50% 的受訪行業專業人士認為監管挑戰是採用創新製造技術的最大障礙。這種不確定性直接限制了市場成長，製藥開發商推遲了對連續生產線的資本投資，直到針對這些自動化系統的清晰、統一的法規結構完全建立並被其品管團隊充分理解。

市場趨勢

一次性技術與連續工作流程的融合，將一次性組件的柔軟性與增強型灌注製程的高生產率相結合，正在革新全球連續生物製程市場。這種協同效應使製造商能夠快速擴大生產規模，並顯著降低資本支出，與傳統的不銹鋼設備相比，這對於在小規模的面積內生產多種生物製藥產品至關重要。藥明生物近期成功部署了超高生產率的連續生產平台，證明了這種混合方法的商業性可行性。根據該公司於2025年3月發布的2024會計年度財務報告，藥明生物運作三個5000公升的一次性生物反應器用於商業化生產，使每克蛋白質的生產成本降低了約70%。這表明，為了保持成本競爭力，整個產業正在果斷地轉向整合式一次性連續生產系統。

同時，隨著細胞和基因治療領域從臨床研究走向商業化生產，連續培養方法在該領域的應用也正在加速發展。為了因應這些複雜治療方法所面臨的規模化挑戰和高昂的生產成本，研發人員正在加速從人工批次處理過程向自動化、封閉式連續工作流程的轉型。這一趨勢的驅動力是大量資金湧入，用於推動先進治療方法生產流程的產業化。根據再生醫學聯盟於2025年1月發布的《產業趨勢簡報》，2024年全球對細胞和基因治療領域的投資將年增30%，顯示市場有強烈的意願克服生產瓶頸。資金的激增正在推動連續技術的應用，而這些技術對於滿足患者對救命治療方法日益成長的需求至關重要。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球連續生物製程市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品（層析法系統及耗材、生物反應器、過濾系統及設備、其他）
  • 按流程（下游流程、上游工程）
  • 按應用領域（單株抗體、疫苗、細胞/基因療法等）
  • 依最終用戶（製藥/生物製藥公司、合約研究組織、學術研究機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美連續生物製程市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲連續生物製程市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區連續生物製程市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲連續生物製程市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲連續生物製程市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球連續生物製程市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• 3M Company
• Merck KgaA
• Sartorius AG
• Eppendorf SE
• Corning Incorporated
• Meissner AG
• OmniBRx Biotechnologies Private Limited
• Bio-Rad Laboratories, Inc.
• Fujifilm Holdings Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Continuous Bioprocessing Market is projected to expand from USD 264.87 Million in 2025 to USD 464.39 Million by 2031, registering a CAGR of 9.81%. This sector revolves around a manufacturing method where biological materials flow continuously through processing units, allowing for the simultaneous addition of raw media and the harvesting of the final product. The primary motivation behind this approach is the need to minimize capital expenditures and facility footprints while simultaneously boosting productivity and flexibility for multi-product manufacturing. This expansion is further bolstered by the strong growth of contract development and manufacturing organizations (CDMOs), which are increasingly adopting these versatile systems to handle diverse pipelines. As noted in the CPHI Annual Report for 2024, 49% of pharmaceutical executives surveyed expressed a 'very positive' outlook on the future growth of contract services, underscoring the industry's dependence on external partners who advocate for these efficient workflows.

Despite these benefits, the widespread adoption of continuous bioprocessing encounters significant hurdles related to the complexity of process control and regulatory alignment. The necessity for advanced Process Analytical Technology (PAT) to monitor critical quality attributes in real-time establishes a substantial technical barrier to entry. This requirement for continuous, automated validation, combined with a shortage of personnel skilled in managing such dynamic systems, can impede implementation efforts, particularly for legacy facilities that are accustomed to traditional batch processing.

Market Driver

Advancements in Process Analytical Technology and Automation serve as a primary catalyst for the Global Continuous Bioprocessing Market by facilitating real-time quality control and minimizing human error. Integrating these automated systems enables manufacturers to monitor critical process parameters continuously, ensuring that deviations can be corrected immediately without halting production. Although this shift is technically demanding, it is essential for upholding the rigorous standards mandated by regulatory bodies for biological products, thereby prompting manufacturers to upgrade legacy systems. According to the 'Horizons: Life Sciences Report' published by CRB in October 2024, approximately 31% of industry professionals surveyed identified digitalization and automation conversion projects as their next primary capital focus, highlighting the sector's dedication to technological upgrades.

The move toward modular and flexible manufacturing facilities further drives market growth by enabling companies to adapt rapidly to changing production requirements and diverse product pipelines. In contrast to traditional fixed stainless-steel facilities, modular units allow for quick reconfiguration to accommodate different modalities, which significantly lowers the barrier to entry for multi-product manufacturing and reduces facility footprints. This trend is illustrated by major pharmaceutical investments aimed at agility; as reported by Becker's Hospital Review in November 2024 regarding Sanofi's new manufacturing plant, the company is establishing a $600 million facility in Singapore designed to produce up to four biopharmaceuticals simultaneously. This initiative aligns with broader industry trends, as CRB data from 2024 indicates that three-quarters of respondents are currently using or planning to implement continuous technologies within the next five years.

Market Challenge

The widespread adoption of continuous bioprocessing is significantly hindered by the rigorous demands of process control and associated regulatory uncertainties. Unlike traditional batch methods, continuous workflows necessitate real-time monitoring and automated feedback loops to preserve product quality, requiring advanced Process Analytical Technology (PAT). This technical complexity results in a steep operational learning curve, as manufacturers must ensure that dynamic control systems remain validated without interruption. Consequently, many companies are hesitant to transition from established batch processes, fearing that an inability to demonstrate consistent control to regulators could result in compliance failures and production delays.

This apprehension regarding compliance is supported by recent industry data. According to the International Society for Pharmaceutical Engineering (ISPE) in 2024, nearly 50% of surveyed industry professionals cited regulatory challenges as the most significant barrier to adopting innovative manufacturing technologies. This prevailing uncertainty directly restricts market growth, as pharmaceutical developers delay capital investments in continuous lines until clear, harmonized regulatory frameworks for these automated systems are fully established and comprehended by their internal quality teams.

Market Trends

The integration of Single-Use Technologies into continuous workflows is revolutionizing the Global Continuous Bioprocessing Market by merging the flexibility of disposable components with the high volumetric productivity of intensified perfusion processes. This synergy permits manufacturers to scale operations rapidly and significantly lower capital expenditures compared to traditional stainless-steel setups, which is a critical advantage for producing diverse biologics within smaller facility footprints. The commercial viability of this hybrid approach was recently validated by WuXi Biologics, which successfully deployed its ultra-high productivity continuous platform at a commercial scale. According to the company's '2024 Annual Results' released in March 2025, WuXi Biologics commissioned three 5,000-liter single-use bioreactors for commercial production, contributing to a cost reduction in protein production per gram of nearly 70%, highlighting the sector's decisive shift toward integrated single-use continuous systems to maintain cost-competitiveness.

Simultaneously, the application of continuous methods to Cell and Gene Therapies is gaining momentum as the sector matures from clinical research to commercial-scale manufacturing. Developers are increasingly transitioning from manual, labor-intensive batch processes to automated, closed continuous workflows to tackle the urgent challenges of scalability and the exorbitant production costs associated with these complex modalities. This trend is driven by a robust influx of capital aimed at industrializing advanced therapy manufacturing. According to the Alliance for Regenerative Medicine's 'State of the Industry Briefing' in January 2025, global investment in the cell and gene therapy sector rose by 30% in 2024, signaling a strong market commitment to overcoming manufacturing bottlenecks. This surge in funding fosters the adoption of continuous technologies that are essential for meeting the growing patient demand for these life-saving therapies.

Key Market Players

• Thermo Fisher Scientific Inc.
• 3M Company
• Merck KgaA
• Sartorius AG
• Eppendorf SE
• Corning Incorporated
• Meissner AG
• OmniBRx Biotechnologies Private Limited
• Bio-Rad Laboratories, Inc.
• Fujifilm Holdings Corporation

Report Scope

In this report, the Global Continuous Bioprocessing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Continuous Bioprocessing Market, By Product

• Chromatography Systems and Consumables
• Bioreactors
• Filtration Systems and Devices
• Others

Continuous Bioprocessing Market, By Process

• Downstream
• Upstream

Continuous Bioprocessing Market, By Application

• Monoclonal Antibodies
• Vaccines
• Cell and Gene Therapy
• Other

Continuous Bioprocessing Market, By End-User

• Pharmaceutical and Biopharmaceutical Companies
• Contract Research Organizations
• Academic and Research Institutes
• Others

Continuous Bioprocessing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Continuous Bioprocessing Market.

Available Customizations:

Global Continuous Bioprocessing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Continuous Bioprocessing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Chromatography Systems and Consumables, Bioreactors, Filtration Systems and Devices, Others)
  • 5.2.2. By Process (Downstream, Upstream)
  • 5.2.3. By Application (Monoclonal Antibodies, Vaccines, Cell and Gene Therapy, Other)
  • 5.2.4. By End-User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations, Academic and Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Continuous Bioprocessing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Process
  • 6.2.3. By Application
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Continuous Bioprocessing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Process
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Continuous Bioprocessing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Process
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Continuous Bioprocessing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Process
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End-User

7. Europe Continuous Bioprocessing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Process
  • 7.2.3. By Application
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Continuous Bioprocessing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Process
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Continuous Bioprocessing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Process
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Continuous Bioprocessing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Process
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Continuous Bioprocessing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Process
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Continuous Bioprocessing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Process
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End-User

8. Asia Pacific Continuous Bioprocessing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Process
  • 8.2.3. By Application
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Continuous Bioprocessing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Process
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Continuous Bioprocessing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Process
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Continuous Bioprocessing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Process
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Continuous Bioprocessing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Process
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Continuous Bioprocessing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Process
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Continuous Bioprocessing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Process
  • 9.2.3. By Application
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Continuous Bioprocessing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Process
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Continuous Bioprocessing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Process
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Continuous Bioprocessing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Process
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End-User

10. South America Continuous Bioprocessing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Process
  • 10.2.3. By Application
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Continuous Bioprocessing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Process
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Continuous Bioprocessing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Process
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Continuous Bioprocessing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Process
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Continuous Bioprocessing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. 3M Company
• 15.3. Merck KgaA
• 15.4. Sartorius AG
• 15.5. Eppendorf SE
• 15.6. Corning Incorporated
• 15.7. Meissner AG
• 15.8. OmniBRx Biotechnologies Private Limited
• 15.9. Bio-Rad Laboratories, Inc.
• 15.10. Fujifilm Holdings Corporation

16. Strategic Recommendations

17. About Us & Disclaimer